Zynex (NasdaqGS:ZYXI) Q3 2025 Earnings Call November 18, 2025 09:00 AM ET Speaker2Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Zynex third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. As a reminder, this conference is being recorded. I would now like to turn the conference over to Vikram Bajaj, Chief Financial Officer of Zynex. Please go ahead.Speaker1Thank you, Operator, and good afternoon, everyone. Yesterday, we rele ...

Core Insights - Zynex, Inc. is undergoing a transformative phase under new management, focusing on overcoming business challenges and enhancing financial health [1] Financial Performance - For Q3 2025, Zynex reported an EPS of -$1.42, significantly below the expected -$0.19, and revenue of $13.36 million, compared to an estimate of $24.53 million, indicating ongoing financial difficulties [2] - The company has a negative P/E ratio of -0.23, reflecting its financial struggles [2] Management Strategy - Zynex's management, led by CEO Steven Dyson, is implementing a three-part strategy aimed at improving compliance, liquidity, and revenue [3] - Despite poor performance in Q3, management emphasizes progress in strategic initiatives to rebuild the company's strength [3] Financial Metrics - The company has a price-to-sales ratio of 0.16 and an enterprise value to sales ratio of 0.70, indicating low market valuation of its sales and revenue [4] - An enterprise value to operating cash flow ratio of -3.67 suggests difficulties in generating positive cash flow [4] Liquidity and Debt - Zynex faces a negative earnings yield of -4.32% and a debt-to-equity ratio of -1.73, indicating more liabilities than equity [5] - The current ratio of 0.47 points to potential liquidity issues, as it is below the standard threshold of 1, suggesting challenges in meeting short-term obligations [5]

Revenue Performance - Net revenue decreased by $36.6 million or 73% to $13.4 million for the three months ended September 30, 2025, compared to $50.0 million for the same period in 2024[168] - For the nine months ended September 30, 2025, net revenue decreased by $84.2 million or 57% to $62.2 million from $146.4 million in the same period in 2024[168] - Device revenue decreased by $7.8 million or 53% to $7.1 million for the three months ended September 30, 2025, from $14.9 million for the same period in 2024[176] - Device revenue decreased by $14.8 million or 33% to $30.0 million for the nine months ended September 30, 2025, from $44.8 million for the same period in 2024[176] - Supplies revenue decreased by $28.8 million or 82% to $6.3 million for Q3 2025, and by $69.3 million or 68% to $32.2 million for the nine months ended September 30, 2025[178] Operational Challenges - Device orders decreased by 35% and 20% for the three and nine months ended September 30, 2025, respectively, compared to the same periods in 2024[168] - The decrease in supplies revenue was significantly impacted by the Tricare payment suspension, resulting in a $13.3 million decline for Q3 2025[179] - Device revenue declined by approximately $2.0 million (from the same period in 2024) due to a temporary Tricare payment suspension and workforce reductions[177] Financial Position - Cash used in operating activities was $23.0 million during the nine months ended September 30, 2025, compared to cash provided by operating activities of $10.3 million during the same period in 2024[169] - Working capital deficit was $41.8 million as of September 30, 2025, compared to working capital of $58.3 million as of December 31, 2024[169] - As of September 30, 2025, the company had $13.3 million in cash and cash equivalents and $6.7 million in net accounts receivable[192] Expenses and Impairments - The company recognized pre-tax non-cash asset impairment charges of $30.7 million during the quarter ended September 30, 2025, primarily related to goodwill and certain fixed assets associated with Zynex Monitoring Solutions[154] - Cost of revenue for devices and supplies decreased by $4.9 million or 48% to $5.3 million for Q3 2025, but as a percentage of revenue, it increased to 40% from 20%[180] - General and administrative expenses decreased by $3.5 million or 23% to $11.8 million for Q3 2025, with the percentage of revenue increasing to 88% from 31%[186] - The company recorded non-cash impairment charges totaling $30.7 million during Q3 2025 related to its ZMS subsidiary[189] Net Loss and Default Risk - The company has incurred net losses of $73.3 million for the nine months ended September 30, 2025, compared to net income of $3.6 million during the same period in 2024[198] - The company has not made an interest payment of approximately $1.5 million due on November 15, 2025, which could lead to an event of default[201] Workforce and Severance - The company expects to incur aggregate pre-tax cash severance charges of approximately $0.7 million in the fourth quarter of 2025 due to workforce reductions[154] - Tricare historically represented approximately 20-25% of the company's annual revenue, with cash collections from Tricare amounting to $48.8 million and $38.8 million for the years ended December 31, 2024 and 2023, respectively[165]

Financial Performance - Net revenue for Q3 2025 was $13.4 million, a decline of 73% compared to $50.0 million in Q3 2024, primarily due to Tricare payment suspension and a $2.8 million revenue reduction during the suspension period[6] - Gross profit for the quarter was $8.1 million, representing 60% of revenue, down from $39.8 million or 80% of revenue in Q3 2024[7] - Net loss for Q3 2025 totaled ($42.9) million, or ($1.42) per share, significantly impacted by a non-cash asset impairment charge of $30.7 million[9] - Adjusted EBITDA loss for Q3 2025 was ($12.3) million, compared to an Adjusted EBITDA of $5.1 million in Q3 2024[10] - Total net revenue for Q3 2025 was $13,360,000, a decrease of 73% compared to $49,966,000 in Q3 2024[20] - Net income (loss) for the nine months ended September 30, 2025, was $(73,343,000), compared to $3,609,000 for the same period in 2024[21] - Adjusted EBITDA for Q3 2025 was $(12,343,000), representing -92% of net revenue, compared to 10% in Q3 2024[23] - Total costs of revenue and operating expenses for Q3 2025 were $57,322,000, an increase from $46,164,000 in Q3 2024[20] Cash Flow and Assets - Cash flow from operations for Q3 2025 was ($6.3) million, with total cash and cash equivalents at $13.3 million as of September 30, 2025[10] - Cash and cash equivalents at the end of Q3 2025 were $13,259,000, down from $37,630,000 at the end of Q3 2024[21] - Total current assets decreased to $37.0 million as of September 30, 2025, down from $75.2 million at the end of 2024[19] Liabilities and Debt - Total liabilities increased to $86.7 million as of September 30, 2025, compared to $86.4 million at the end of 2024[19] - Zynex has entered a 30-day grace period and will not make a $1.5 million interest payment on its $60 million Convertible Notes due in May 2026[4] - The company incurred interest expense of $890,000 in Q3 2025, compared to $625,000 in Q3 2024[20] Revenue Breakdown - Devices revenue for Q3 2025 was $7,057,000, down from $14,858,000 in Q3 2024[20] - Supplies revenue for Q3 2025 was $6,303,000, compared to $35,108,000 in Q3 2024[20] Expenses - Sales and marketing expenses decreased by 54% to $9.5 million from $20.7 million in Q3 2024, primarily due to reduced sales force headcount[8] - The company reported impairment charges of $30,740,000 for the nine months ended September 30, 2025[20] Strategic Initiatives - The company has engaged Province, LLC to evaluate strategic alternatives, including potential capital raising and restructuring strategies[3] Shareholder Information - Weighted average basic shares outstanding decreased to 30,314,000 in Q3 2025 from 31,775,000 in Q3 2024[20]

Core Insights - Zynex, Inc. reported a significant decline in net revenue for Q3 2025, totaling $13.4 million, down from $50.0 million in the same quarter of the previous year, primarily due to a Tricare payment suspension and operational challenges [4][7][8] Management Commentary and Strategic Initiatives - The new management team, led by CEO Steven Dyson, is focused on compliance, liquidity challenges, and improving revenue and cash flow performance [2] - Zynex has engaged Province, LLC for strategic alternatives, including potential capital raising and restructuring strategies [2][3] - A Special Committee has been formed to oversee the evaluation of these strategic alternatives [3] Financial Performance - Gross profit for Q3 2025 was $8.1 million, representing 60% of revenue, compared to $39.8 million or 80% of revenue in Q3 2024 [5] - Sales and marketing expenses decreased by 54% to $9.5 million, while general and administrative expenses were $11.8 million, down from $15.3 million in the prior year [6] - The net loss for Q3 2025 was ($42.9) million, or ($1.42) per share, influenced by a non-cash asset impairment charge of $30.7 million [7][8] Cash Flow and Liquidity - Cash flow from operations for Q3 2025 was ($6.3) million, with total cash and cash equivalents at $13.3 million as of September 30, 2025 [8] - The company has opted for a 30-day grace period on a $1.5 million interest payment due on its $60 million Convertible Notes [3] Balance Sheet Overview - As of September 30, 2025, total assets were $45.3 million, a significant decrease from $122.1 million at the end of 2024 [15][16] - Current liabilities increased to $78.8 million, primarily due to the current portion of convertible senior notes [15][16]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - Zynex, Inc. is implementing strategic initiatives to ensure long-term success, including engaging a financial advisory firm and forming a Special Committee to explore various strategic alternatives [1][2][5]. Strategic Initiatives - Zynex has engaged Province, LLC to evaluate strategic alternatives, including capital raising and restructuring strategies [2]. - A Special Committee has been formed by the Board, consisting of independent directors, to oversee the assessment of these strategic alternatives [4]. Leadership Changes - Paul Aronzon has been appointed to the Board of Directors, bringing over 40 years of experience in corporate restructuring and advisory roles [3]. - Aronzon will serve as Chair of the Special Committee, which will work closely with management and Province to assess strategic options [4]. Management Statements - CEO Steven Dyson emphasized the company's commitment to exploring all avenues for a new future for Zynex through these strategic steps [5].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4][5] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [5]

Core Insights - Zynex, Inc. has appointed Bret Wise to its Board of Directors, where he will also serve as Chair of the Audit Committee, indicating a strategic move towards enhancing governance and oversight [1][4]. Company Overview - Zynex, Inc. specializes in the manufacture and sale of non-invasive medical devices aimed at pain management, rehabilitation, and patient monitoring [1][9]. - The company was founded in 1996 and has developed a range of medical devices, including those for fluid, sepsis, and laser-based pulse oximetry monitoring systems for hospital use [9]. Leadership and Expertise - Bret Wise brings extensive operational and financial management experience from the medical device industry, having previously served as Chair and CEO of Dentsply International and Executive Chair of Dentsply Sirona [2][3]. - His past roles include Chief Financial Officer of two publicly traded companies and audit partner at KPMG, showcasing a strong background in financial oversight [3]. Strategic Direction - The appointment of Bret Wise is seen as a pivotal moment for Zynex, with a focus on refocusing the company's mission around patient and customer success, integrity, and compliance [2][4]. - The leadership believes that Mr. Wise's financial expertise will significantly enhance Zynex's commitment to high standards of financial oversight and transparency [4].